セフィキシム
Based on 9 publication(s) in Google Scholar
Cefixime (FR-17027) is an orally active antibiotic and a third generation cephalosporin antibiotic, useful for the treatment of a number of bacterial infections.
For research use only. We do not sell to patients.
- Purity: 99.94%
- CAS No.: 79350-37-1
- Formula: C16H15N5O7S2
- Molecular Weight:453.45
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Antibacterial Compound Library
HY-L049
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Cefixime
More- J Adv Res. 2024 Oct 21:S2090-1232(24)00472-7. [Abstract]
- ACS Environ Au. 2025 Aug 5;5(6):573-582. [Abstract]
- Clin Transl Med. 2024 Oct;14(10):e70035. [Abstract]
- Anal Chem. 2025 Jun 3;97(21):11099-11109. [Abstract]
- PLoS Pathog. 2024 Dec 31;20(12):e1012783. [Abstract]
- FASEB J. 2026 Jan 31;40(2):e71438. [Abstract]
- Microbiol Spectr. 2023 Jun 15;11(3):e0069223. [Abstract]
- Biomed Res Int. 2018 Jul 2:2018:3579832. [Abstract]
- University of Texas. 2025.
All Antibiotic Isoforms
More
Biological Activity
|
β-lactam |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Caco-2 | IC50 |
10 mM
Compound: Cefixime
|
TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 5 uM) in Caco-2 cells
TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 5 uM) in Caco-2 cells
|
[PMID: 9092716] |
Cefixime shows great antibacterial activity against clinical isolates of Salmonella typhi, with a MIC90 value of 0.25 μg/mL, and is also active against β-lactamase producing Amoxicillin (HY-B0467A)-resistant strains[3].
Cefixime is also active against Enterobacteriaceae, such as Haemophilus influenzae, and Neisseria gonorrhoeae[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
cefixime (50 or 150 mg/kg, oral gavage) changes the structure and abundance of the gut microbiota of C57BL/6J mice, specifically, a reduction in the diversities of the microbial community and decreasing to one preponderant Firmicutes phylum[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 79350-37-1
-
Appearance Solid
-
Molecular Weight 453.45
-
Formula C16H15N5O7S2
-
Color White to light yellow
-
SMILES
O=C(C1=C(C=C)CS[C@]([H])([C@@H]2NC(/C(C3=CSC(N)=N3)=N\OCC(O)=O)=O)N1C2=O)O
-
Synonyms
Cefixime
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
J Adv Res
The gut microbiotas with metabolites regulate the protective role of miR-30a-5p in myocardial infarction. [Abstract]2024 Oct 21:S2090-1232(24)00472-7. PMID: 39442873 -
ACS Environ Au
Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]2025 Aug 5;5(6):573-582. PMID: 41277996 -
Clin Transl Med
Gut microbiota of miR-30a-5p-deleted mice aggravate high-fat diet-induced hepatic steatosis by regulating arachidonic acid metabolic pathway. [Abstract]2024 Oct;14(10):e70035. PMID: 39360667 -
Anal Chem
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]2025 Jun 3;97(21):11099-11109. PMID: 40401576 -
PLoS Pathog
Differential contribution of PBP occupancy and efflux on the effectiveness of β-lactams at their target site in clinical isolates of Neisseria gonorrhoeae. [Abstract]2024 Dec 31;20(12):e1012783. PMID: 39739989 -
FASEB J
Enhancing the Susceptibility of Methicillin-Resistant Staphylococcus aureus to β-Lactam Antibiotics Through the Use of 4-Methoxysalicyl Aldehyde. [Abstract]2026 Jan 31;40(2):e71438. PMID: 41524623 -
Microbiol Spectr
Penicillin-Binding Protein Occupancy Dataset for 18 β-Lactams and 4 β-Lactamase Inhibitors in Neisseria gonorrhoeae. [Abstract]2023 Jun 15;11(3):e0069223. PMID: 37093051 -
Biomed Res Int
In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Mycobacterium tuberculosis Clinical Isolates. [Abstract]2018 Jul 2:2018:3579832. PMID: 30065936 -
Solvent & Solubility
DMSO : 100 mg/mL (220.53 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.51 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.51 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Neu HC, et al. In vitro activity of a new broad spectrum, beta-lactamase-stable oral cephalosporin, cefixime. Pediatr Infect Dis J. 1987 Oct;6(10):958-62. [Content Brief]
[2]. Unemo M, et al. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012 Mar;56(3):1273-80. [Content Brief]
[3]. Matsumoto Y, et al. Antibacterial activity of cefixime against Salmonella typhi and applicability of Etest. J Infect Chemother. 1999 Sep;5(3):176-179. [Content Brief]
[4]. Connolly KL, et al. Pharmacokinetic Data Are Predictive of In Vivo Efficacy for Cefixime and Ceftriaxone against Susceptible and Resistant Neisseria gonorrhoeae Strains in the Gonorrhea Mouse Model. Antimicrob Agents Chemother. 2019 Feb 26;63(3):e01644-18. [Content Brief]
[5]. Shi Y, et al. Restoration of cefixime-induced gut microbiota changes by Lactobacillus cocktails and fructooligosaccharides in a mouse model. Microbiol Res. 2017 Jul;200:14-24. [Content Brief]
[6]. Stone JW, et al. Cefixime, in-vitro activity, pharmacokinetics and tissue penetration. J Antimicrob Chemother. 1989 Feb;23(2):221-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2053 mL | 11.0266 mL | 22.0531 mL | 55.1329 mL |
| 5 mM | 0.4411 mL | 2.2053 mL | 4.4106 mL | 11.0266 mL | |
| 10 mM | 0.2205 mL | 1.1027 mL | 2.2053 mL | 5.5133 mL | |
| 15 mM | 0.1470 mL | 0.7351 mL | 1.4702 mL | 3.6755 mL | |
| 20 mM | 0.1103 mL | 0.5513 mL | 1.1027 mL | 2.7566 mL | |
| 25 mM | 0.0882 mL | 0.4411 mL | 0.8821 mL | 2.2053 mL | |
| 30 mM | 0.0735 mL | 0.3676 mL | 0.7351 mL | 1.8378 mL | |
| 40 mM | 0.0551 mL | 0.2757 mL | 0.5513 mL | 1.3783 mL | |
| 50 mM | 0.0441 mL | 0.2205 mL | 0.4411 mL | 1.1027 mL | |
| 60 mM | 0.0368 mL | 0.1838 mL | 0.3676 mL | 0.9189 mL | |
| 80 mM | 0.0276 mL | 0.1378 mL | 0.2757 mL | 0.6892 mL | |
| 100 mM | 0.0221 mL | 0.1103 mL | 0.2205 mL | 0.5513 mL |
Powered by Bioz